Want to see GB:RENX full AI Analyst Report?
Renalytix (RENX) AI Stock Analysis
Renalytix
(LSE:RENX)
The score is primarily constrained by severe financial risk, including persistent losses, negative equity, debt exceeding assets, and continued cash burn. Technical conditions are moderately supportive, but the negative P/E and absence of income offset that support.
Renalytix (RENX) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 36.54M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.67M
- Price to Earnings (P/E)
- -3.4
- Beta (1Y)
- -0.53
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- UK
- Employees
- 46
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Renalytix Business Overview & Revenue Model
Company Description
Renalytix Plc specializes in developing cutting-edge in vitro diagnostic solutions for kidney diseases, leveraging the power of artificial intelligence. Their primary offering, KidneyIntelX, is an advanced diagnostic platform. It employs a sophistica...
Renalytix Earnings Call Summary
The earnings call highlighted significant strategic achievements, including Medicare coverage developments, inclusion in clinical guidelines, successful fundraising, and cost reduction efforts. However, there are challenges such as a decline in revenue and testing volumes, and adoption hurdles in the VA system. The sentiment is balanced, with positive long-term strategic developments countered by short-term operational challenges.
Q3-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the third quarter earnings call for Renalytix (Symbol: RENX.L), management provided a detailed overview of their financial and strategic progress. The company reported a revenue of $535,000 for Q3 2024, with 806 tests processed, 82% of which were billable. This reflects a decline from the previous year, attributed to the conclusion of a $6 million contract with Mount Sinai. Operating expenses were significantly reduced by 40% year-over-year to $6.5 million, following strategic reorganization efforts, including a 50% reduction in headcount. The net loss also decreased by 36% to $7.7 million. The launch of the FDA-authorized KidneyIntelX.dkd product and increased insurance reimbursement were highlighted as key developments. The company emphasized their strategic focus on sales growth with a 33% increase in direct-to-physician test orders quarter-over-quarter, while anticipating further growth with the expected finalization of Medicare coverage and inclusion in international clinical guidelines. Additionally, Renalytix raised $13.5 million in aggregate gross proceeds from recent financings and reported $4.7 million in cash as of March 31, excluding additional financing proceeds. The ongoing strategic review, including potential acquisition interest, was also discussed, though specifics were limited due to regulatory constraints.
Renalytix Financial Statement Overview
Summary
Severe financial weakness drives the minimum score: the company remains deeply unprofitable, has negative equity, debt exceeding assets, and materially negative cash flow. Lower losses, debt, and cash burn provide limited improvement.
Income Statement
25NegativeBalance Sheet
10Very NegativeCash Flow
20Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Sep 2024 | Jun 2023 | Sep 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.60M | 3.01M | 3.00M | 2.29M | 3.40M | 2.97M |
| Gross Profit | 800.00K | 1.10M | 1.20M | 156.00K | 701.00K | 874.00K |
| EBITDA | 0 | -13.83M | -21.30M | -28.52M | -41.71M | -52.69M |
| Net Income | -8.10M | -14.24M | -20.40M | -33.46M | -45.61M | -45.28M |
Balance Sheet | ||||||
| Total Assets | 9.90M | 4.62M | 6.10M | 7.97M | 30.63M | 50.06M |
| Cash, Cash Equivalents and Short-Term Investments | 6.20M | 1.41M | 3.70M | 5.40M | 24.68M | 41.33M |
| Total Debt | 5.80M | 5.73M | 8.30M | 8.54M | 12.15M | 12.34M |
| Total Liabilities | 11.10M | 10.96M | 13.10M | 15.83M | 23.66M | 19.46M |
| Stockholders Equity | -1.20M | -6.33M | -7.00M | -7.85M | 6.97M | 30.61M |
Cash Flow | ||||||
| Free Cash Flow | -5.50M | -11.03M | -17.90M | -30.11M | -32.67M | -46.44M |
| Operating Cash Flow | -5.40M | -10.93M | -17.90M | -30.11M | -34.09M | -45.74M |
| Investing Cash Flow | -100.00K | -100.25K | 0 | -4,000 | 0 | -694.00K |
| Financing Cash Flow | 8.60M | 8.72M | 16.00M | 10.25M | 16.39M | 25.52M |
Renalytix Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:RENX, the sentiment is Neutral. The current price of 5.45 is below the 20-day moving average (MA) of 5.60, above the 50-day MA of 5.45, and above the 200-day MA of 3.56, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 45.58 is Neutral, neither overbought nor oversold. The STOCH value of 36.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:RENX.
Renalytix Risk Analysis
Renalytix disclosed 91 risk factors in its most recent earnings report. Renalytix reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskRenalytix Peers Comparison
Overall Rating
GB:EKF64Neutral
GB:GDR49Neutral
GB:VRCI44Neutral- GB:RENX43Neutral
GB:OBD40Underperform
GB:PRM37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:EKF | 64Neutral | GBP 102.71M | 41.38 | 3.58% | ― | 2.26% | -57.04% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:GDR | 49Neutral | GBP 15.65M | -0.89 | -1044.57% | ― | 65.60% | 74.84% |
| GB:VRCI | 44Neutral | GBP 15.32M | -0.60 | -127.57% | ― | 77.87% | 84.36% |
| GB:RENX | 43Neutral | GBP 36.54M | -3.44 | 675.00% | ― | ― | ― |
| GB:OBD | 40Underperform | GBP 14.45M | -0.27 | -451.74% | ― | 33.37% | 86.41% |
| GB:PRM | 37Underperform | GBP 5.10M | -1.99 | 23.85% | ― | -16.72% | 36.28% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:RENX | Renalytix Plc OTC | 5.45 | -1.80 | -24.83% | |
| GB:EKF | EKF Diagnostics Holdings | 23.50 | -2.50 | -9.62% | |
| GB:GDR | Genedrive plc | 0.97 | -0.04 | -3.75% | |
| GB:OBD | Oxford BioDynamics | 0.10 | -0.22 | -68.13% | |
| GB:PRM | Proteome Sciences | 1.46 | -0.19 | -11.55% | |
| GB:VRCI | Verici Dx Plc | 0.23 | -0.40 | -63.20% |
Renalytix Corporate Events
Renalytix Set to Benefit as U.S. Kidney Care Plan Backs Precision Prevention
PositiveRenalytix plc is accelerating its push into U.S. kidney care with kidneyintelX.dkd, an FDA-authorized and Medicare-reimbursed prognostic blood test designed for adults with type 2 diabetes and early-stage chronic kidney disease. The AI-enabled platfo...
Renalytix Director Christopher Mills Increases Shareholding After Equity Placing
PositiveRenalytix plc reported that investment vehicles linked to non-executive director Christopher Mills purchased 1,166,667 ordinary shares at £0.06 each on 29 September 2026. Following the transaction, Mills and his connected vehicles hold 18,201,69...
Renalytix Director Lifts Stake as AI Kidney Test Gains Commercial Traction
PositiveRenalytix plc disclosed that investment vehicles linked to Non-Executive Director Christopher Mills acquired 1,166,667 ordinary shares at £0.06 each, lifting his total interest to 18,201,690 shares, or about 2.7% of the enlarged share capital. T...
Renalytix Shareholders Back Fundraising as New Shares Join AIM
PositiveRenalytix plc reported that all resolutions put to shareholders at its General Meeting were passed, paving the way to complete a recently announced capital raise and strengthen its balance sheet by eliminating all convertible debt. The company has se...
Renalytix Chair to Step Down as Company Advances U.S. Kidney Test Rollout
PositiveRenalytix has announced that Non-Executive Chair Julian Baines will step down from the board at the end of 2026, marking the latest leadership transition at the kidney disease diagnostics specialist. Baines, who helped steer the company through a rec...
Renalytix boosts investor engagement as KidneyIntelX gains commercial traction
PositiveRenalytix will step up its investor outreach with a live online presentation hosted by CEO James McCullough on 29 September and a double slot at the MelloLondon2026 conference on 17 November, where shareholders and prospective investors can engage di...
Renalytix CEO Increases Stake as AI Kidney Test Gains U.S. Traction
PositiveRenalytix plc, listed in London and on the OTCQB, operates in the precision medicine diagnostics sector with a focus on kidney disease, leveraging AI-enabled in vitro diagnostics to guide clinical management. Its kidneyintelX.dkd test, developed with...
Renalytix Aligns Year-End Reporting With Calendar Year Ahead of Quest Partnership
PositiveRenalytix plc has changed its accounting reference date, shifting its financial year-end from 30 June to 31 December and creating an 18‑month transition period ending 31 December 2026. The company will report audited results for this extended p...
Renalytix CEO Boosts Stake as Kidney Diagnostics Platform Scales in U.S.
PositiveRenalytix reported that CEO James McCullough purchased 340 American Depositary Shares on 8 and 9 September at an average price of $3.875 each, lifting his beneficial interest to 3,447,096 ordinary shares, or about 0.57% of the company’s issued...
Renalytix Seeks Shareholder Approval for Fundraising to Scale Kidney Diagnostics
PositiveRenalytix plc has distributed a shareholder circular and notice of a general meeting to approve fundraising-related resolutions, with the materials also made available on its investor website. The meeting is scheduled for 28 September 2026 in London,...
Renalytix Raises £10.5 Million and Prepares Second Tranche Share Admission on AIM
PositiveRenalytix has completed its WRAP Retail Offer at £0.06 per share, raising about £380,000, which supplements the £10.1 million already secured via a placing and subscription. In total, the placing, subscription and retail offer have gen...
Renalytix Opens £1 Million WRAP Retail Offer Alongside £10.1 Million Fundraise
PositiveRenalytix has launched a retail offer via the Winterflood Retail Access Platform to raise up to £1 million by issuing as many as 16,666,666 new ordinary shares at 6 pence each, matching the price of its recently completed institutional placing a...
Renalytix Raises £10.1m and Wipes Out HCM Debt to Fund U.S. Kidney Test Expansion
PositiveRenalytix has completed a significantly oversubscribed equity fundraise, conditionally securing gross proceeds of £10.1 million through a placing and subscription of 168,366,151 new shares at 6 pence, and a total transaction value of £13.6...
Renalytix raises £9.5m to fund U.S. kidney-test rollout and cuts debt via bond conversion
PositiveRenalytix plc plans to raise at least £9.5 million in gross proceeds through a placing, subscription and a retail offer at 6 pence per share, a significant premium to its recent trading price, to fund a newly signed strategic collaboration in th...
Renalytix partners with Quest to expand U.S. rollout of kidneyintelX.dkd test
PositiveRenalytix, a precision medicine diagnostics company specializing in AI-enabled tests for kidney disease, develops the kidneyintelX.dkd blood test to predict the risk of progressive kidney function decline in adults with type 2 diabetes and early-stag...
Renalytix Discloses Director’s Link to Trellus Administration as KidneyIntelX Rollout Advances
PositiveRenalytix plc, a London- and New York-based precision medicine diagnostics group, specializes in artificial intelligence-enabled in vitro tests to optimize kidney disease management and outcomes. Its lead product, kidneyintelX.dkd, holds FDA approval...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 02, 2026